1201790-19-3

Basic information

• Product Name: tert-butyl N-[3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propyl]carbamate
• Synonyms: tert-butyl N-[3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propyl]carbamate
• CAS NO: 1201790-19-3
• Molecular Weight: 377.289
• Mol File: 1201790-19-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: tert-butyl N-[3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl N-[3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propyl]carbamate(1201790-19-3)
• EPA Substance Registry System: tert-butyl N-[3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propyl]carbamate(1201790-19-3)

Safety Data

• Hazardous Substances Data: 1201790-19-3(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 73183-34-3 bis(pinacol)diborane 
• 106-41-2 4-bromo-phenol 
• 83948-53-2 3-bromopropylamine tert-butylcarbamate 
• 269409-70-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 
• 34619-03-9 tert-butyldicarbonate 
• 76-09-5 2,3-dimethyl-2,3-butane diol 
• 71597-85-8 (p-hydroxyphenyl)boronic acid 
• 116861-31-5 tert-butyl N-(3-chloropropyl)carbamate 

Downstream Products

• 1417520-26-3 C₃₇H₄₅N₃O₄ 
• 1620955-45-4 C₂₉H₃₁N₅O₄ 
• 1620955-46-5 2-(4'-(3-aminopropoxy)-[1,1'-biphenyl]-4-yl)-1,6-naphthyridine-4-carbohydrazide hydrochloride 
• 1620955-44-3 C₃₀H₃₁N₃O₅ 

Relevant articles and documents

Fluorescence opening type diarylethene fluorescent probe, and preparation method and application thereof

The invention provides a fluorescence opening type diarylethene fluorescent probe, and a preparation method and application thereof. The fluorescence opening type diarylethene fluorescent probe has a structure as shown in a formula I, the probe is compose

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.